|

XNW5004 tablets Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Evopoint Biosciences Inc.1

Indications

  • Follicular Lymphoma, Grade 21
  • Follicular Lymphoma, Grade 11
  • Follicular Lymphoma Grade 31
  • Follicular Lymphoma Grade 3A1
  • Cancer1

Other1 trial

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.